# Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy

Source: https://onco.cc/trials/nct06385990/  
OnCo record `nct06385990` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of utidelone in triple-negative breast cancer, run by Hunan Cancer Hospital, now recruiting.

## Summary

Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy is a phase 2, interventional study registered as NCT06385990 by Hunan Cancer Hospital, with a registry enrolment figure of 53 participants, started 2024-03-29 and due to reach its primary completion in 2025-03-29. Interventions recorded: UTD1. Conditions listed: Triple Negative Breast Neoplasms. Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06385990
- Phase: 2
- Setting: Clinical Study of the Efficacy and Safety of Utidelone (UTD1) Combined With Capecitabine as Adjuvant Therapy in Non-pCR Triple-negative Breast Cancer Patients After Neoadjuvant Therapy
- Sponsor: Hunan Cancer Hospital
- Enrolled: 53

## Sources

- ClinicalTrials.gov NCT06385990: https://clinicaltrials.gov/study/NCT06385990

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Utidelone](https://onco.cc/drugs/utidelone/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06385990.json